Human Genome Sciences Inc. (“HGS”, the “Company”, “we”, “our” and “us”) is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Our lead products are BENLYSTA® (belimumab) for systemic lupus erythematosus (“SLE”) and raxibacumab for inhalation anthrax. BENLYSTA was approved on March 9, 2011 by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard therapy. We launched BENLYSTA shortly thereafter and recognized revenue from our first BENLYSTA sales in March 2011. On July 13, 2011, the European Commission granted marketing authorization for BENLYSTA as an add-on therapy in adult patients with active autoantibody-positive SLE, with a high degree of disease activity despite standard therapy. BENLYSTA is currently available in the United States, Canada and an increasing number of European countries including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden. In addition, regulatory submissions are pending in other countries.
Company profile
Ticker
HGSI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
223178468
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Aug 12
EFFECT
Notice of effectiveness
10 Aug 12
CT ORDER
Confidential treatment order
9 Aug 12
CT ORDER
Confidential treatment order
9 Aug 12
POS AM
Prospectus update (post-effective amendment)
9 Aug 12
POSASR
Automatic shelf registration (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 12
Latest ownership filings
SC 13D/A
GAMCO INVESTORS, INC. ET AL
31 Jul 12
SC 13D
GAMCO INVESTORS, INC. ET AL
20 Jul 12
11-K
Annual report of employee stock purchases
28 Mar 12
11-K
Annual report of employee stock purchases
31 Mar 11
11-K
Annual report of employee stock purchases
29 Mar 10
11-K
Annual report of employee stock purchases
30 Mar 09
11-K
Annual report of employee stock purchases
31 Mar 08
11-K
Annual report of employee stock purchases
29 Mar 07
11-K
Annual report of employee stock purchases
30 Mar 06
11-K
Annual report of employee stock purchases
29 Mar 05
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 0.00 | $0.00 |